STRATEGY ADVISORY FOR LIFE SCIENCES

STRATEGY ADVISORY FOR LIFE SCIENCES

Know your market

before you commit.

Know your market

before you commit.

Know your market

before you commit.

A senior team gives you clear answers in weeks on patients, payers, competitors and revenue. For the teams deciding what to develop, license, launch or invest in.

Patients in the claims dataPatients our rebuild found

RECENT WORK

RECENT WORK

How big is this rare disease market, really?

How big is this rare disease market, really?

How big is this rare disease market, really?

0
0

sources used to rebuild the market

Claims estimate

Our rebuild

Medicaid patients added

The rebuild added a Medicaid population to the team’s estimate.

See our work

PHASE 1 TO YEAR 1

PHASE 1 TO YEAR 1

Answers ready before

each stage’s decision

Answers ready before

each stage’s decision

Answers ready before

each stage’s decision

We answer the questions each stage raises while there’s still time to act on the answer.

Phase 1
Pick where to start
Unmet need
Lead indication
Patient numbers
Phase 2a
Test the market case
Treatable patients
Treatment choice
Competitor readouts
Phase 2b
Shape the product profile
Eligible patients
Comparators
Gaps payers will probe
Phase 3
Build the value story
Payer criteria
Undiagnosed patients
Cost offsets
Filing
Plan for the label
Covered patients
Payer mix
Price range
Launch
Reach the right patients
Patient finding
Specialist access
Prescriptions to starts
Year 1
Close the gap to forecast
Uptake
Persistence
Next indication

FOR YOUR TEAM

FOR YOUR TEAM

Answers shaped to your role

Answers shaped to your role

Answers shaped to your role

Pick a stage
The Decision
Set the emerging product profile
What You Need to Know
1How many patients match the benefit we're seeing?
2Why would a physician switch from today's treatment?
3Which outcomes will payers want later?
What You Get
A patient funnel for the emerging profile and the outcomes to measure before Phase 3.

WHY ASSUMPTIONS MATTER

WHY ASSUMPTIONS MATTER

One assumption can move peak revenue by $234M a year

One assumption can move peak revenue by $234M a year

One assumption can move peak revenue by $234M a year

Every forecast rests on a few assumptions: who is eligible, what payers will cover, what price they accept and how fast physicians prescribe. Each one starts as an estimate. We check them against published studies, payer policies and public data, so you commit budget on numbers that hold up.

What we check
Pick an assumption
Example: one coverage rule
In one rare inherited bleeding disorder, the coverage rule decides whether 6,100 or 13,900 patients qualify.
Narrow coverage
Only patients on IV iron or transfusions · 6,100 patients
$183M a year at peak
Broad coverage
All coded patients with anemia · 13,900 patients
$417M a year at peak
The difference$0Ma year at peak
What it changes
1How big a field team you hire
2How much launch budget you commit
3Which price and access strategy you choose
Patient counts: Al-Samkari et al., Am J Hematol 2025 (US claims, 2022). Price ($100,000 a year net) and uptake (30% of eligible patients) are the same in both cases, so only the coverage rule changes.

WHERE WE FIT

WHERE WE FIT

Checked answers for big decisions

in days to weeks

Checked answers for big decisions

in days to weeks

Checked answers for big decisions

in days to weeks

Good for
Time to an answer
Confidence in the answer
What it misses
General AI tools
A quick first take
Days
DaysWeeksMonths
Unchecked: sources can be wrong or missing
Patient-level data, and checks on its own sources
Market research firms
Hearing directly from physicians and patients
Months
DaysWeeksMonths
Depends on who answers the survey
Patients and physicians outside the sample
Strategy consultancies
Company-wide strategy and large programs
Months
DaysWeeksMonths
Strong when the data behind it is complete
Whatever the licensed data behind it doesn't cover
Our approach
Massive Insights
One big decision, answered in days to weeks
Days to weeks
DaysWeeksMonths
Each number traced to its source
Not a data subscription or an ongoing tracker

RECENT WORK

RECENT WORK

Recent answers

teams put to work

Recent answers

teams put to work

Recent answers

teams put to work

CASE 01

How big is this rare disease market, really?

0

sources used to rebuild the market from the ground up

WHAT IT GAVE THE TEAM

Gave the team a second view against its claims estimate, and found a Medicaid population the claims data missed.

CASE 01

How big is this rare disease market, really?

0

sources used to rebuild the market from the ground up

WHAT IT GAVE THE TEAM

Gave the team a second view against its claims estimate, and found a Medicaid population the claims data missed.

CASE 01

How big is this rare disease market, really?

0

sources used to rebuild the market from the ground up

WHAT IT GAVE THE TEAM

Gave the team a second view against its claims estimate, and found a Medicaid population the claims data missed.

CASE 02

Where should a diagnostic relaunch start?

0

urgent care organizations sized and ranked

WHAT IT GAVE THE TEAM

Gave the team a starting list ranked by segment and owner.

CASE 02

Where should a diagnostic relaunch start?

0

urgent care organizations sized and ranked

WHAT IT GAVE THE TEAM

Gave the team a starting list ranked by segment and owner.

CASE 02

Where should a diagnostic relaunch start?

0

urgent care organizations sized and ranked

WHAT IT GAVE THE TEAM

Gave the team a starting list ranked by segment and owner.

CASE 03

Who treats, and where, for a Phase 3 oncology asset?

~0

treating oncologists and their key centers on one map

WHAT IT GAVE THE TEAM

Gave the launch team a named and sized view of who treats and where.

CASE 03

Who treats, and where, for a Phase 3 oncology asset?

~0

treating oncologists and their key centers on one map

WHAT IT GAVE THE TEAM

Gave the launch team a named and sized view of who treats and where.

CASE 03

Who treats, and where, for a Phase 3 oncology asset?

~0

treating oncologists and their key centers on one map

WHAT IT GAVE THE TEAM

Gave the launch team a named and sized view of who treats and where.

WHY MASSIVE INSIGHTS

WHY MASSIVE INSIGHTS

Answers in weeks

from our

Health Lake

Answers in weeks

from our

Health Lake

Answers in weeks

from our

Health Lake

Our Health Lake brings prescribing, procedure, payment and payer data together, so a project starts from data that is already in place.

0+
0+
0+
Prescribing data
Procedure data
Payment data
Medicaid data
900+ in all
Each column is one clinicianHighlighted: one clinician linked across sources

public data sources catalogued in our Health Lake, most already cleaned and joined clinician by clinician

COVERAGE

COVERAGE

Public data first, your data if you want it

Most answers come from public sources. We add your own data only when it helps the question.

SOURCES

SOURCES

Sources picked for each decision

We also choose how to connect them and which model answers the decision in front of you.

PEOPLE

PEOPLE

20+ years in life sciences commercialization

Strategists with big pharma and small biotech experience interpret the results, and every number traces to its source.

HOW IT WORKS

HOW IT WORKS

Three steps

from question to answer

Three steps

from question to answer

Three steps

from question to answer

We find the facts that settle the decision in front of you.

PrescribingProceduresPaymentsMedicaidPayer policiesStudiesClaimsExperts(Your data)Answer

Public sources combine into one answer. Your own data is optional.

01

You bring a question

Tell us what’s pressing and what depends on it. We start by agreeing on the exact question to answer.

02

We pull together the public data that answers it

More than 900 public sources, from prescribing and payment data to payer policies and published studies, most already cleaned and joined in our Health Lake. If it helps, we add your own data or a few expert, patient or payer conversations.

03

You get the answer, and everything behind it

The answer and what to do about it. An executive read-out written for the room you need to convince.

Who to go after first, named, sized and ranked, when that’s what you need.

The sources and calculations behind each number, so your team can check our work.

A working session with your team to walk through it.

TEAM

TEAM

Senior people, start to finish

Senior people, start to finish

Senior people, start to finish

Senior life sciences strategists run every project from the first call to the final read-out.

Julie Batten

LIFE SCIENCES PRACTICE LEAD & COO

LIFE SCIENCES PRACTICE LEAD & COO

More than a decade of launches at big pharma and small biotech.

Part of the founding leadership team at Katalyst, a Klick company.

Brian O’Donnell

CHIEF STRATEGY & INSIGHTS OFFICER

CHIEF STRATEGY & INSIGHTS OFFICER

Leads how we combine public data into answers for commercial decisions.

20+ years in life sciences commercialization. Leads our use of AI to find and check sources.

MARKET READS

MARKET READS

See what’s changing

in your therapy area

See what’s changing

in your therapy area

See what’s changing

in your therapy area

Short reads on the markets we track and the numbers behind them. Request a copy of any read and we’ll email it to you.

MARKET LANDSCAPE

Chronic spontaneous urticaria

~400K

US candidates for advanced therapy

MARKET LANDSCAPE

Chronic spontaneous urticaria

~400K

US candidates for advanced therapy

CSU · OCT 2026

Three mechanisms now compete in chronic hives

For over a decade, CSU patients not controlled on antihistamines had one biologic option. Three mechanisms are now approved, and a fourth could follow by 2028. Here is the market after Celldex’s Phase 3 readout.

Request a copy

(5 pages)

MARKET READ

Pyoderma gangrenosum

~15,000

US adults with a PG diagnosis

MARKET READ

Pyoderma gangrenosum

~15,000

US adults with a PG diagnosis

PYODERMA GANGRENOSUM · SEPT 2026

Five signals that matter for a US launch in PG

A disease claims data barely sees. What public procedure, prescribing and payment data says about where patients are, who sees them first, and what a launch has to beat.

Request a copy

(4 pages)

MARKET BRIEF

IgA nephropathy

6 brands

approved in the US for IgAN since 2021

MARKET BRIEF

IgA nephropathy

6 brands

approved in the US for IgAN since 2021

IGA NEPHROPATHY · SEPT 2026

Six IgAN brands approved since 2021, all tested as add-on therapies

No late-stage IgAN trial goes head-to-head with an approved brand. Through 2028, brands compete on sequence and combination.

Request a copy

(2 pages)

FAQ

FAQ

Before you ask

Before you ask

Before you ask

We’re pre-approval. Isn’t it too early?

Pre-approval is often the best time to start. A market snapshot, a sizing or a check on your launch assumptions feeds your budget and launch plan before the big decisions are locked in.

We’re small and budgets are tight. Can we afford this?

Most teams use research budget already set aside and get answers in weeks instead of waiting on a six-month study. You can start with a market snapshot or one focused question a commercial lead can approve alone. There are no long contracts, and you can stop after any phase.

Our disease area has thin data.

That’s where combining many sources matters most. No single dataset sees a rare market well.

We already have an agency or insights team.

We work alongside them on the work they don’t have time for. We sell no media, creative or data.

Is this just AI?

AI helps us search more sources faster, and senior people check every result before it reaches you.

GET STARTED

GET STARTED

What’s the decision with the most at stake?

What’s the decision with the most at stake?

What’s the decision with the most at stake?

Tell us about your program and the decision ahead. Julie Batten will reply directly with how we’d approach it. Not ready yet? Request a market read or see the FAQ.

Before you commission a six-month study, start here

Before you commission a six-month study, start here

Before you commission a six-month study, start here

Each has a fixed scope and fee and no long contract.

Each has a fixed scope and fee and no long contract.

01

Market snapshot

A short first read of your market.

Start here

02

Focused question sprint

One hard question, answered in weeks.

Start here

03

Second opinion

Pressure-test a forecast, plan or launch assumption before it goes to the board.

Start here

Julie Batten

Life Sciences Practice Lead

Bring us your question